Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 30, 1998

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
BIOLOGICAL

oregovomab

Trial Locations (16)

19111

Fox Chase Cancer Center, Philadelphia

21202

Mercy Medical Center, Inc., Baltimore

22908

Cancer Center, University of Virginia HSC, Charlottesville

23601

Riverside Regional Medical Center, Newport News

29203

Palmetto Richland Memorial Hospital, Columbia

32804

Walt Disney Memorial Cancer Institute, Orlando

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

33902

Lee Memorial Health System, Fort Myers

52242

University of Iowa Hospitals and Clinics, Iowa City

63110

Barnes-Jewish Hospital, St Louis

63141

St. John's Mercy Medical Center, St Louis

73190

University of Oklahoma College of Medicine, Oklahoma City

75246

Texas Oncology, P.A., Dallas

92663

Gynecologic Oncology Associates, Newport Beach

46202-5265

Indiana University Cancer Center, Indianapolis

K1H 8L6

Ottawa Regional Cancer Center - General Division, Ottawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AltaRex

INDUSTRY

NCT00004064 - Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | Biotech Hunter | Biotech Hunter